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BehaviorParkinson's disease (PD) is a neurodegenerative disorder classically characterized by the death of dopamine (DA)
neurons in the substantia nigra pars compacta and by intracellular Lewy bodies composed largely ofα-synuclein.
Approximately 5–10%of PD patients have a familial formof Parkinsonism, includingmutations inα-synuclein. To
better understand the cell-type speciﬁc role of α-synuclein on DA neurotransmission, and the effects of the
disease-associated A30P mutation, we generated and studied a novel transgenic model of PD. We expressed
the A30P mutant form of human α-synuclein in a spatially-relevant manner from the 111 kb SNCA genomic
DNA locus on a bacterial artiﬁcial chromosome (BAC) insert on a mouse null (Snca−/−) background. The BAC
transgenic mice expressed α-synuclein in tyrosine hydroxylase-positive neurons and expression of either
A30P α-synuclein or wildtype α-synuclein restored the sensitivity of DA neurons to MPTP in resistant
Snca−/− animals. A30P α-synuclein mice showed no Lewy body-like aggregation, and did not lose catechol-
amine neurons in substantia nigra or locus coeruleus. However, using cyclic voltammetry at carbon-ﬁber micro-
electrodeswe identiﬁed a deﬁcit in evokedDA release in the caudate putamen, but not in the nucleus accumbens,
of SNCA-A30P Snca−/− mice but no changes to release of another catecholamine, norepinephrine (NE), in the
NE-rich ventral bed nucleus of stria terminalis. SNCA-A30P Snca−/−mice had no overt behavioral impairments
but exhibited a mild increase in wheel-running. In summary, this reﬁned PD mouse model shows that A30P α-
synuclein preferentially perturbs the dopaminergic system in the dorsal striatum, reﬂecting the region-speciﬁc
change seen in PD.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. Introduction
Parkinson's disease (PD) is a debilitating neurodegenerative disease,
second in prevalence to Alzheimer's disease. PD is primarily considered
a dopaminergic disorder, characterized bymotor phenotypes, including
resting tremor, bradykinesia, rigidity and postural instability (Dauer
and Przedborski, 2003; Olanow and Tatton, 1999). Post-mortem
PD brain tissue shows loss of midbrain dopamine (DA) neurons and
accumulation of Lewy bodies, protein aggregates largely composed ofAnatomy, and Genetics, Le Gros
ford OX1 3QX, UK.
(R. Wade-Martins).
ect.com).
.Open access under CC BY license. α-synuclein. The onset of classical parkinsonism is frequently preceded
by a prodromal phase, with symptoms ranging from sleep disturbances
to gastrointestinal dysfunction (Braak et al., 2003; Langston, 2006).
These non-motor changes likely arise from changes in neurotransmis-
sion in non-dopaminergic systems.
Approximately 5–10% of PD cases are familial and rare dominant
familial PD has been linked to the point mutations A53T, E46K, and
A30P in α-synuclein (SNCA) on chromosome 4 (Kruger et al., 2001;
Polymeropoulos et al., 1997; Zarranz et al., 2004). Recent post-mortem
neuropathological analysis of a PD patient with an A30P α-synuclein
mutation showed strong neuropathological similarities between A30P
and idiopathic PD patients (Seidel et al., 2010), conﬁrming the relevance
of the mutation to PD. The function(s) of α-synuclein, a 140 amino acid
protein highly abundant in presynaptic terminals, are incompletely re-
solved. In PD, α-synuclein accumulation and Lewy body formation
occur early in structures highly prone to neurodegeneration (Braak
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synuclein aggregation is not required for neuronal loss (Fernagut and
Chesselet, 2004).
Despite relatively few familial PD patients, genetic-based animal
models have been integral to furthering knowledge about PD. Histori-
cally, genetic models of α-synuclein dysfunction have yielded a fatal
motor syndrome, often in the absence of overt dopaminergic alter-
ations. These models have had signiﬁcant limitations due to the use of
promoters that do not reproduce the endogenous pattern of neuronal
gene expression (Chesselet, 2008). Furthermore, α-synuclein, either
mutated and/or overexpressed, can damage neurons; however, the
resulting degenerationmay have limited relevance to PD (Sulzer, 2010).
To better understand the cell-type speciﬁc role ofα-synuclein on DA
neurotransmission, and the non-toxic physiological effects of the
disease-associated A30P mutation, we have generated and studied a
novel transgenicmodel of PD.Weused a bacterial artiﬁcial chromosome
(BAC), containing the complete 111 kb SNCA genomicDNA locus to gen-
erate transgenicmicewhich express either humanα-synuclein carrying
the PD-associated A30P mutation or human wild-type α-synuclein as a
control, on an α-synuclein knockout (Snca−/−) background. Expres-
sion of either A30P α-synuclein or wildtype α-synuclein restored the
sensitivity of dopaminergic neurons to MPTP in resistant Snca−/− an-
imals. We demonstrate here that the SNCA-A30P Snca−/−mice exhibit
a deﬁcit in DA neurotransmission in the dorsal, but not ventral, striatum
as shown by fast-scan cyclic voltammetry (FCV), suggesting a speciﬁc
role forα-synuclein in the nigrostriatal systempreferentially vulnerable
in PD. To investigate the role of α-synuclein and the effect of the A30P
mutation on neurotransmission of another catecholamine, norepineph-
rine, we developed an FCV assay to explore norepinephrine neurotrans-
mission in the ventral bed nucleus stria terminalis (vBNST), but we ﬁnd
no signiﬁcant changes in the SNCA-A30P Snca−/− line. These mice
provide a novel model to study differential region-speciﬁc effects of
α-synuclein on dopamine neurotransmission.
Materials and methods
Breeding
Male and female mice lacking α-synuclein (Snca−/−) were main-
tained as a pure-bred C57BL6 background (Abeliovich et al., 2000).
Bacterial artiﬁcial chromosomal (BAC) DNA containing SNCA transgenes
encoding either the wild-type SNCA locus (Peruzzi et al., 2009) or the
A30P mutation engineered using standard BAC recombineering
methods were prepared by CsCl double banding for microinjection
into pure C57/Bl6 (Charles River, Margate, UK) mouse pronuclei.
Founder pups were screened for the presence of the intact transgene
by PCR and breeding lines were established. The resulting lines wereTable 1
List of primer sequences used for PCR. All PCR primer sequences are given 5′– 3′.
Name Forward primer
Mouse SncaWT CAGCTCAAGTTCAGCCACGA
Mouse Snca KO CAGCTCAAGTTCAGCCACGA
BAC-SNCA CACTGAGTATTGTTCTGGTAAC
5 junction
BAC-SNCA GGCCTCTGTCGTTTCCTTTCTCTG
3′ junction
SNCA Exon 1 ATCCGAGATAGGGACGAGGAG
SNCA Exon 2 CCGAAAGTTCTCATTCAAAGTG
SNCA Exon 3 GAAAACTAGCTAATCAGCAATTTAA
GG
SNCA Exon 4 CCACCCTTTAATCTGTTGTTGC
SNCA Exon 5 TCATCATGTTCTTTTTGTGCTTC
SNCA Exon 6 AACAGTGTGTGCTGTCTTTTTGbackcrossed for a minimum of six generations to C57/Bl6 Snca−/−
mice to obtain N99% pure C57/Bl6 background, resulting in SNCA-
A30P + Snca−/− (referred to as A30P) and SNCA-WT+ Snca−/−
(referred to as hα-syn) mice. All transgenic lines were maintained as
hemizygotes. All animal work was performed in accordance with the
United Kingdom Animals (Scientiﬁc Procedures) Act (1986).
Polymerase chain reaction (PCR)
Genotyping was carried out to identify the mice carrying the BAC-
SNCA transgenes. PCR was used to amplify the wild-type or knock-out
Snca−/− alleles, and to amplify the junctions between the BAC vector
and the SNCA genomic DNA insert. Exon PCR was used to conﬁrm all
six exons from the BAC inserts were present. Separate master mixes
were prepared for each primer pair. The primer sequences used were
previously designed in our laboratory and are listed in Table 1. PCR am-
pliﬁcation conditions were denaturing for 15 min at 95 °C, followed by
44 cycles of 30 s at 95 °C, 30 s at 60 °C, and 1 min at 72 °C (35 cycles
for exon PCR).
Fluorescence in situ hybridization (FISH)
The protocol used for extraction of primary ﬁbroblasts wasmodiﬁed
from Kulnane and colleagues (Kulnane et al., 2002). FISH was per-
formed using the SNCA BAC as a probe on primary ﬁbroblasts as previ-
ously described (Jefferson and Volpi, 2010).
MPTP treatment in mice
Animals (male and female) were injected intraperitoneally
three times, spaced two hours apart, with either saline or 15 mg/kg
of the dopaminergic neurotoxin MPTP (free base). Animals were
sacriﬁced 7 days afterMPTP administration for analysis of dopaminergic
markers.
Western immunoblotting analysis
Western blotswere used to quantify the amount of tyrosine hydrox-
ylase (TH), dopamine transporter (DAT), humanα-synuclein, and actin
present in samples of striatal tissue and were performed as described
previously (Caudle et al., 2006). Membranes were incubated overnight
in a TH monoclonal antibody (1:1000; Chemicon) and detected using a
goat anti-rabbit horseradish peroxidase secondary antibody (1:5000)
and visualized by enhanced chemiluminescence using an ECL kit (GE).
Membranes were stripped for 15 min at room temperature with
Restore Stripping Buffer (Thermo Fisher, Rockford, IL, USA) and sequen-
tially re-probedwith DAT (1:5000; Chemicon), and humanα-synucleinReverse primer Product size
AAGGAAAGCCGAGTGATGTAC 485 bp
ATGGAAGGATTGGAGCTACG 550 bp
TCAAACATGAGAATTGGTCG 450 bp
ACGTGCATAGGCAGAGCTAAA 450 bp
ACCT
AATAGGAAAGAAGAAGGAAAA 465 bp
GGAG
TGACATTTGGGGTTTACCTACC 206 bp
AATCTTGAATACTGGGCCACAC 182 bp
CACAAAACGTACACAGCCATA
C
203 bp
TGTGACAATGACAGGTTTTTGG 182 bp
AGATTGAAGCCACAAAATCCA 317 bp
C
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loading across samples.
For MPTP sample analysis, striata were mechanically homogenized
in RIPA buffer and cytosolic fractions taken prepared for reducing, dena-
turing SDS-PAGE. Proteins were separated on 10.5–14.5 % gradient gels
and transferred using a Trans-Blot Turbo transfer system (Bio-Rad, UK).
Membranes were blocked and probed with polyclonal rabbit anti-
tyrosine hydroxylase (Millipore, AB152) or polyclonal rabbit anti β-
actin antibody (Abcam, AB8227) and visualized with HRP conjugated
anti-rabbit IgG (Bio-Rad, UK). Densitometry analysis was performed
using ImageJ software.
Immunohistochemistry
Tissue stainingwas completed as previously described (Caudle et al.,
2006; Miller et al., 1997, 1999). Brieﬂy, A30P, hα-syn, and Snca−/−
mice were perfused transcardially with phosphate buffered saline
(pH= 7.4) and then with 4% paraformaldehyde, removed, placed in
4% paraformaldehyde for 24 h, and ﬁnally cryoprotected in 30% sucrose
for 48 h. The brains were then cut to a thickness of 40 μm a freezingmi-
crotome (Leica Microsystems). Sections were incubated with a poly-
clonal anti-TH (1:2000; Chemicon), monoclonal anti-DAT (1:750;
Chemicon), or monoclonal anti-α-synuclein (1:500; BD Biosciences)
antibody overnight and then incubated in a biotinylated goat anti-
rabbit, goat anti-rat, or goat ant-mouse secondary antibody for 1 h at
room temperature. Visualization was performed using 3, 3´-diamino-
benzidine (DAB) for 45 s at room temperature. After DAB, all sections
were mounted on slides, dehydrated, and coverslipped using DPX
Mountant (Fluka Biochemika) and sections were viewed using a light
microscope (Leica).
To detect potentialα-synuclein-related pathology, we used immuno-
histochemical staining by monoclonal antibodies (MAb) Syn-1 (1:1000,
BD Transduction Labs) against aa 91–99, LB509 (1:1000, Invitrogen)
against amino acids (aa) 115–122 of α-syn and pSyn#64 (1:5000,
Wako) against aa124–134 (including phosphorylated Ser129) on parafﬁn
sections. Other antibodies includedMAb anti-TH (1:100, Millipore); anti-
Iba-1 (1:2000,WAKO); polyclonal anti-p62 (1:5000, Enzo) and anti-GFAP
(1:4000, Dako). The ﬁxed brain and spinal cord were embedded in paraf-
ﬁn and cut into 6 μm-thick sections, deparafﬁnised and rehydrated.
Peroxidase activitywas eliminatedwith treatmentwith 3%H2O2 followed
by pre-treatmentswith formic acid for 15 min (for Syn-1), formic acid for
5 min together with autoclaving (121 °C) for 10 min in citrate buffer (for
LB509, Iba-1, p62 and TH), 20 μl/ml proteinase K (Roche, UK) treatment
for 10 min (for pSyn#64), microwaving in citrate buffer for 3 × 5min
(for GFAP). The mouse-on-mouse kit (M.O.M., Vector Labs) was used to
MAb to minimize the background and staining was visualized using
DAB (Vector Labs).
Fast scan cyclic voltammetry
Brain slice preparation
Adult Snca−/−; A30P and hα-syn mice (aged 3–4 months) were
sacriﬁced by cervical dislocation and decapitated; their brains were re-
moved over ice. Coronal brain slices (300 μm thick) containing the stri-
atum or the ventral nucleus of the bed nucleus stria terminalis (vBNST)
were prepared using a vibratome (Leica Microsystems) in ice-cold
HEPES-based buffer saturated with 95% O2/5% CO2 as described previ-
ously (Cragg, 2003; Rice and Cragg, 2004). Slices were maintained at
room temperature in HEPES-based buffer for ≥1 h before transfer to
the recording chamber where slices were equilibrated for at least
30 min in the recording solution, a bicarbonate-buffered artiﬁcial CSF
(containing 2.4 mm Ca2+)(Cragg, 2003; Rice and Cragg, 2004).
Voltammetry
Extracellular catecholamines were monitored and quantiﬁed in the
dorsal and ventral striatum at 32 °C using fast-scan cyclic voltammetry(FCV) as previously described (Rice and Cragg, 2004) with 10 μm-
diameter carbon-ﬁber microelectrodes (exposed tip length, 50–100 μm,
fabricated in-house) and a Millar voltammeter (Julian Millar, Barts and
The London School of Medicine and Dentistry, London, UK). The applied
voltage was a triangular waveform (−0.7 to +1.3 V range vs. Ag/AgCl)
at a scan rate of 800 V/s and a frequency of 8 Hz, and was switched out
of circuit between scans. Electrodes were positioned in striatal slices to
a depth of 100 μm. Catecholamine release was evoked by a surface,
concentric bipolar Pt/Ir electrode (25 μm diameter; FHC) as described
previously (Rice and Cragg, 2004).
Striatal dopamine detection
Individual data points were collected through one of two experi-
mental designs. In the ﬁrst paradigm, evoked extracellular DA concen-
trations [DA]o were assessed and compared across several sites per
slice (6–8 sites per CPu, 2 per NAc) in both genotypes on the same
experimental day. DA release datawere collected from six different sub-
divisions, encompassing the dorsal and ventral CPu: Speciﬁcally, record-
ings were obtained from dorso-medial, dorso-central, dorso-lateral,
central, ventro-medial and ventro-lateral regions. Stimuli in these ex-
periments consisted of either a single pulse or burst pulses (4 pulses
at 100 Hz). In the second stimulation paradigm, the frequency depen-
dence of release was determined, through recordings taken repeatedly
at given recording sites (2.5 min intervals ensured consistent release)
and consisted of single pulses and trains of 5 pulses at a range of fre-
quencies (1–100 Hz) applied in randomized order. These frequencies
include the full range of dopaminergic neuron ﬁring frequencies reported
in vivo. Recordings in these experiments in CPu were in the dorsal half of
the nucleus, and those in NAc were ventral to the anterior commissure
and lateral to the lateral ventricle.
Stimulus pulses were generated out-of-phase with FCV scans and
were applied at the lowest current that generated maximal dopamine
release with a single stimulus pulse in wild-type animals (650 μA,
200 μs pulse duration). Evoked currents were attributable to DA by
the presence of oxidation and reduction currents with peak potentials
seen for DA in calibration media (+500–600 mV and−200mV vs Ag/
AgCl, respectively).
DA uptake rates were compared between genotypes by comparing
the decay phases of DA transient proﬁles evoked by a single pulse. DA
uptake via DAT is the principal factor governing DA decay in these
evoked transients (Giros et al., 1996). The rate of DA uptake by the
DAT obeys Michaelis–Menton kinetics and is therefore proportional to
Vmax and varies with [DA]o. Comparison of the decay phase of DA tran-
sients matched for similar peak [DA]o eliminates differences in uptake
rate due to [DA]o, therefore any prevailing differences in Vmax should
be apparent (Cragg et al., 2000). DA transients were concentration-
matched for a peak of 1.0 ± 0.01 μM from ﬁve animals for each
genotype.
Norepinephrine detection in vBNST
Extracellular norepinephrine (NE) was monitored and quantiﬁed in
the ventral bed nucleus of the stria terminalis (vBNST). Catecholamine
detection using FCV has previously been described in vBNST (Miles
et al., 2002) although the distinction between DA and NE had not
been previously made. Evoked signals were readily attributable to
catecholamines (NE/DA) by comparison of potentials for peak oxidation
and reduction currents with those seen in calibration media post-
experiment (1–2 μM) (approximately −600 mV and−200 mV vs Ag/
AgCl, respectively). NE and DA have similar oxidation and reduction
peak potentials, however, we attributed these signals to NE rather
than DA, by identifying that these signalswere regulated byα2 adrener-
gic receptors and by the NE transporter (NET) unlike DA signals detect-
ed in the adjacent striatum. Unless otherwise stated, individual data
points were obtained from recordings taken repeatedly at a single
recording site at 7 min intervals, to ensure consistent release (Miles
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(10–100 Hz) in randomized order.
FCV analysis
Data were acquired and analyzed using Strathclyde Whole Cell Pro-
gram (University of Strathclyde, Glasgow, UK) or Axoscope 10.2 (Molec-
ular Devices). The number of animals in each data set is N5. Comparisons
for differences in means were assessed by one-way ANOVA and post
hoc Bonferroni's multiple-comparison t test or unpaired t test using
GraphPad Prism 4.0. For FCV data where absolute [DA]o were compared
across many striatal regions and slices between genotypes, all observa-
tions were treated as independent since data were obtained from differ-
ent regions within a given striatum which show large variation due to
striatal territory, a variation that is greater than that between slices.
HPLC
Tissue catecholamine contents were assessed from tissue punches
by HPLC with electrochemical detection (ECD) as described previously
(Al-Wandi et al., 2010; Senior et al., 2008) using a 4.6 × 150 mm
Microsorb C18 reverse-phase column (Varian) and Decade II ECD with
a Glassy carbon working electrode (Antec Leyden) set at +0.7 V with
respect to a Ag/AgCl reference electrode. For measuring dopamine and
its metabolites, the mobile phase consisted of 12% methanol (v/v),
0.1 M monosodium phosphate, 2.4 mM 1-octane sulfonic acid (OSA),
0.68 mM EDTA, pH 3.1. For norepinephrine, a mobile phase of the
same composition but containing 3.2 mM OSA was used.
Stereological analysis
Stereological sampling was performed using the Stereo Investigator
software (MicroBrightField, Colchester, VT). Tissue staining was per-
formed as described previously (McCormack et al., 2002; Reveron
et al., 2002). Whole brains were removed and processed for frozen sec-
tions as described above, and serially sectioned at 50 μm for systematic
analysis of randomly placed counting frames (size 50 × 50 μm) on a
counting grid (size of 120 × 160 μm) and sampled using a 22 μmoptical
dissector with 2 μm upper and lower guard zones. The boundaries of
substantia nigra pars compacta (SNpc) and locus coeruleus (LC) were
outlined under magniﬁcation of the 10× objective as per the atlas of
Paxinos and Franklin (2001). Cells were counted with a 40× objective
(1.3 numerical aperture) using a Nikon Eclipse e800 microscope.
Guard zones of 2 μm ensured the exclusion of lost proﬁles on the top
and bottom of the section sampled. A dopaminergic or noradrenergic
neuron was deﬁned as an in-focus tyrosine hydroxylase immunoreac-
tive (TH-IR) cell body with a TH-negative nucleus within the counting
frame. For the SNpc, every other section was processed for TH-IR and
counterstained with hematoxylin, resulting in 15 sections sampled per
mouse. For the LC, every section was stained for TH-IR and counter-
stained with hematoxylin, resulting in 18–20 sections sampled per
mouse. The number of neurons in the SNpc and LC was estimated
using the optical fractionator method, which is unaffected by changes
in the volume of reference of the structure sampled (West et al.,
1991). Between 100 (LC) and 200 objects (SNpc) were counted to gen-
erate the stereological estimates. Gundersen (m=1) coefﬁcients of
error were less than 0.1.
Behavior
Locomotor activity
To measure novelty-induced locomotor activity, experiments were
conducted in the light phase in an isolated behavior room between
800 and 1200 h. Ambulations were measured in transparent plexiglass
cages placed into a rack with seven infrared photobeams (San Diego In-
struments Inc., LaJolla, CA). Ambulations were recorded for 4 h (Schank
et al., 2006). Tomeasure circadian locomotor activity, micewere placed
in the plexiglass cages and ambulationswere recorded for two 24-h ses-
sions of normal 12-h light/dark cycle (12:12 LD) and averaged.Forepaw stride length
Prior to testing, animals were trained to walk across a clean sheet of
paper into their home cage without stopping. Animals had their fore-
paws placed in black ink and the length of forepaw steps during normal
walking (in a straight line only) was measured; animals were immedi-
ately placed back into their home cage upon completion of the task.
Stride lengths were determined by measuring the distance between
each step on the same side of the body, measuring from the middle
toe of the ﬁrst step to the heel of the second step and averaging the
stride length per animal (Tillerson et al., 2002).
Rotarod
Animals were placed on an accelerating rotarod at the same time
daily for 3 consecutive days, receiving 3 trials per day. The rotarod
was accelerated from 4 to 40 revolutions per minute (RPMs) over a
5 min trial period. The latency to fall off the rotarod was recorded.
Circadian screen
Age-matched animals were individually housed in cages ﬁtted with
running wheels (Actimetrics) maintained at constant temperature and
humidity, with ad libitum food and water. Cages were arranged in light-
controlled chambers with externally controlled LED lighting, with light
levels assessed at cage level using a lux meter. A behavioral screen was
used to examine common circadian paradigms, consisting of: 1) 14 days
entrainment under a 12-h 150 lux light/dark (12:12 LD) cycle (lights off
at ZT12 where ZT0= 0600), 2) 1 day negative masking using a 1 h light
pulse at ZT14, 3) 14 further days of 12:12 LD, 4) 1 day 6-h phase advance,
followed by 21 days of re-entrainment (12:12 LD, ZT0= 0000), 5)
14 days under constant dark (DD) to measure free-running period, 6)
14 days under constant light (150 lux LL) and 7) Return to 12:12 LD
ZT0= 1200 for 14 days. Data analysis was carried out using 10 min
bins of wheel running activity using Clocklab (Actimetrics) software.
Elevated plus maze
The elevated plus maze (EPM) paradigm was adapted from Schank
and colleagues (Schank et al., 2008; Taylor et al., 2009). No drugs were
administered prior to behavioral testing. Videotapes were later scored
by an observer who was blind to genotype. The measure used for anal-
ysis is the percentage of time spent exploring the open arms, whichwas
calculated by dividing the time spent in the open arms by the combined
time spent in open and closed arms (Pellowet al., 1985). Data frommale
and female mice were combined, since there were no detectable sex
differences.
Tail suspension test
These experiments were conducted using themethods of Cryan and
colleagues (Cryan et al., 2004; Taylor et al., 2009). Mice were individu-
ally suspended by the tail to a horizontal ring stand bar (distance from
the ﬂoor = 30 cm) using adhesive tape. A 5-min test session was
videotaped and scored by a trained observer for escape-oriented behav-
ior and bouts of immobility.
One hour stool collection
Each mouse was placed in a separate clean cage, without bedding,
and observed throughout a 60 min collection period. Fecal pellets
were collected immediately after expulsion and placed in sealed (to
avoid evaporation) 1.5 ml tubes. Tubes were weighed to obtain the
wet weight of the stool, this was then dried overnight at 60 °C and
reweighed to obtain the dry weight and the stool water content (Li
et al., 2006; Taylor et al., 2009).
Spontaneous alternation in a T-maze
Spontaneous alternation in an enclosed T-maze was performed as
described previously (Deacon and Rawlins, 2006). The apparatus
consisted of a black T-shaped wooden maze made of arms, measuring
30 cm in length, 10 cm in width, and 29 cm in height. The goal arm
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tion wall, extending 7 cm into the start arm, divided the choice point
into two goal arms to prevent the mouse from receiving any sensory
input from the non-visited arm. A mouse was placed in the start arm
of the T-maze and allowed to choose a goal arm. The mouse was then
conﬁned to the goal arm by sliding the guillotine door down. The arm
entered (left or right) was recorded and the mouse was allowed to ex-
plore the goal arm for 30 s. The mouse was returned to the start arm,
with the guillotine doors re-opened and the central partition removed,
and allowed to explore again. The goal arm entered on the second run
was recorded (left or right) and the mouse was then returned to its
home cage. Each mouse was tested twice each day for 5 days (a total
of 10 trials). The percentage of trials in which the mouse entered a dif-
ferent goal arm on the second run (i.e. alternated) was calculated. Data
frommale and femalemicewere combined, since therewere no detect-
able sex differences.
Statistical analysis
Data from male and female mice were combined, since there were
no detectable sex differences. All data were analyzed using one-way
ANOVA (dot test, bodyweight, stool collection) completely randomized
two-factor ANOVA followed by Bonferroni post hoc analysis (EPM, tail
suspension test, T-maze, stride length, novelty-induced locomotor ac-
tivity). Analyses were completed using Graph Pad Prism 4.0 for
Windows.
Results
Generation of SNCA-WT Snca−/− and SNCA-A30P + Snca−/−mice
The human PD-associated SNCA A30P point mutation was
engineered into a human genomic DNA BAC construct derived from
clone PAC-27 M07 using positive/negative selection/counter-selection
homologous recombination in E. coli as previously described (Alegre-
Abarrategui et al., 2009). The 135 kb genomicDNA SNCABAC insert con-
tains the 111 kb SNCA locus, ﬂanked by 18 kb of 5′ and 6 kb of 3′ geno-
mic DNA sequence (Fig. 1A). The inclusion of 18 kb of 5′ promoter
ensures the presence of the NACP-Rep1 repeat element which lies
approximately 10 kb upstream of the transcriptional start site, and is
an important regulatory element (Jakes et al., 1994; Ueda et al., 1993).
Previous work has shown strongest promoter activity is found from
constructs containing at least 6.2 kb of upstream DNA (Chiba-Falek
et al., 2003, 2005; Chiba-Falek and Nussbaum, 2001; Touchman et al.,
2001; Xia et al., 2001). The accuracy of the recombineering was con-
ﬁrmed by restriction enzyme analysis and DNA sequencing. Transgenic
founder animals identiﬁed as carrying intact BAC inserts following pro-
nuclear injection of wild-type or A30Pmutant SNCA BAC constructs into
a C57/Bl6 background were used to establish breeding lines. The lines
were backcrossed onto amouse C57/Bl6 Snca−/− knockout (KO) back-
ground for a minimum of six generations to remove the endogenousα-
synuclein, producing lines hemizygous for either the wild-type SNCA or
the SNCA-A30P transgene on a pure C57Bl/6 Snca−/− background, to
generate, respectively SNCA-WT+ Snca−/− (referred to as hα-syn)
or SNCA-A30P+ Snca−/− (referred to as A30P). Importantly, back-
crossing to a Snca−/− background avoids the previously-reported con-
founding effect of endogenous mouseα-synuclein expression on trans-
gene function (Cabin et al., 2005).
The presence of all SNCA exons in both the transgenic hα-syn and
A30P lines was conﬁrmed by PCR using primers speciﬁc to human
DNA (Fig. 1B), and the site of BAC integration for both lines was identi-
ﬁed by ﬂuorescence in situ hybridization (FISH) (Fig. 1C). Western blot
analysis conﬁrmed expression of the human α-synuclein protein in the
brains of the hα-syn and A30P lines at similar levels; however, SNCA
transgene expression was signiﬁcantly less than endogenous mouse
α-synuclein in C57/Bl6 mouse brain (Fig. 1D). Immunohistochemical
analysis in coronal brain sections of hα-syn and A30P mice revealed aspatial pattern of α-synuclein expression that recapitulates the pattern
of endogenous α-synuclein protein in wild-type C57/Bl6 mice. Regions
showing α-synuclein protein expression include the cerebral cortex,
hippocampus, striatum, and importantly the SNpc and VTA (Fig. 1E).
Immunohistochemical analysis of α-synuclein expression in dopaminergic
neurons in SNCA-BAC transgenic mice
Fluorescent double-labeling for tyrosine hydroxylase (TH) and α-
synuclein in neuronal slices conﬁrmed accurate physiological expres-
sion of the α-synuclein transgene in TH-positive cells in the substantia
nigra pars compacta (SNpc), the region most commonly associated
with neuronal degeneration in PD (Fig. 2). Intracellularly, α-synuclein
protein was observed in the axons, cell bodies and in the nucleus in
A30P mice, hα-syn mice and wild-type C57/BL6 mice. This demon-
strates that the presence of α-synuclein in the cell body and nucleus is
a physiologically normal feature and is not a consequence of the A30P
mutation. Double-label immunoﬂuorescence staining of sections
followed by cell count analysis showed that 47.6 ± 3.2% of TH+ cells
in the SNpc in the A30P line at 6 months of age also expressed
α-synuclein (n=3 mice).
Expression of wild-type or A30P SNCA restores sensitivity to MPTP in
Snca−/− mice
We next investigated whether the expression of the wild-type or
A30P mutant α-synuclein restored the sensitivity of DA neurons to
the dopaminergic neurotoxin, MPTP, in otherwise resistant Snca−/−
animals. When challenged with an acute dose of MPTP, both the hα-
syn and A30P mice were found to be equally susceptible to nigral and
striatal damage by histological observation of TH staining (Fig. 3A)
and by unbiased stereological analysis of the SNpc (Fig. 3B) whereas
the Snca−/−KO littermatewas resistant toMPTP-induced nigrostriatal
damage as previously reported (Dauer et al., 2002; Thomas et al., 2011).
In the SNpc, both hα-syn and A30P animals demonstrated a 30% loss of
TH+ neurons in response to MPTP treatment, while there was no
change in MPTP-treated Snca−/− KO animals as analyzed by two-
way ANOVA with Bonferroni post-hoc tests (hα-syn: saline: 7003 ±
296, MPTP: 4626± 372; A30P: saline:7358 ± 599, MPTP: 4963 ±669;
KO: saline: 6735 ± 533, MPTP: 7816 ± 53; interaction between treat-
ment and genotype: p= 0.0137, F(2,10) = 6.79, n= 3). Loss of dopami-
nergic neuronmarkers in the striatumof hα-syn andA30P lines, but not
in Snca−/− KO animals, following MPTP treatmentwas also conﬁrmed
by quantitative analysis of TH protein levels by western blotting in
striatal lysates (Figs. 3C, D). These data show that the A30P mutant is
functionally equivalent to the wild-type α-synuclein in being able to
restore sensitivity to MPTP.
A30P transgenic mice display deﬁcits in electrically evoked release of dopa-
mine but not norepinephrine
We ﬁrst assessed the release and re-uptake of DA in the CPu andNAc
using FCV in A30P and hα-syn transgenic mice and compared to
Snca−/− (KO) littermate controls. We have previously shown that
Snca−/− mice show the same evoked [DA]o in response to a single
stimulus or a burst stimulus as wild-type mice (Senior et al., 2008)
allowing us to use the Snca−/− KO littermates as controls. When we
compared evoked [DA]o in Snca−/− KO animals to the hα-syn animals,
no differences were seen after a single stimulus pulse (1p) in the CPu or
NAc (Figs. 4A, B; CPu: Snca−/−KO: 2.13 ± 0.098, n= 60 sites; hα-syn:
2.298 ± 0.099, n=60 sites; 5 animals per genotype, p= 0.23, t-test:
t= 1.216, df = 118; NAc: Snca−/− KO: 0.70 ± 0.1, n=18 sites;
hα-syn: 0.73 ± 0.11, n= 18 sites; 5 animals per genotype, p= 0.87,
t-test: t=0.1674, df = 34). However, in the CPu from A30P mice,
evoked [DA]o were signiﬁcantly reduced (~13%) compared to
Snca−/− KO after either a single stimulus pulse (1p) (Snca−/− KO:
Fig. 1. Expression of humanwild-type or A30Pmutantα-synuclein in SNCA-BAC transgenicmice. A, Schematic representation of the human SNCA BAC transgene constructs carrying either
wild-type or A30Pmutant SNCA. B, Conﬁrmation of the SNCA BAC transgene integrity by PCR in both SNCA lines. Human-speciﬁc PCR primers spanning each of the SNCA coding exonswere
used (exons 1–6). C, Location of transgene integration in SNCA-BAC lines. Fluorescent in situ hybridization (FISH) conﬁrmed a single integration site for both transgenic lines using BAC
probes in combination with chromosome painting. The SNCA-A30P transgene integration was observed near the telomere on one copy of chromosome 15; the SNCA-WT (hα-syn) trans-
gene integration occurred near the telomere on one copy of chromosome 2. D, Expression ofα-synuclein was quantiﬁed by western blot of whole brain homogenates from 3 month-old
SNCA BACmice. α-synuclein expression was quantiﬁed relative to actin levels and normalized to expression in mice expressing wildtype humanα-synuclein (hα-syn). The difference in
expression between A30P and hα-syn lines is not signiﬁcant. n= 3, **p b 0.01. E, Immunohistochemical analysis in coronal brain sections of 3-month old animals revealed α-synuclein
transgene expression in the cortex, SNpc, and VTA in hα-syn and SNCA-A30Pmice recapitulating a spatial pattern of expression almost identical to that of endogenousα-synuclein protein
in wild-type C57Bl6 mice. α-synuclein expression was not seen in Snca−/− KO animals.
198 T.N. Taylor et al. / Neurobiology of Disease 62 (2014) 193–2072.63 ±0.11 μM, n= 96 sites; A30P: 2.29 ± 0.10 μM, n= 92 sites; 9 an-
imals per genotype, p= 0.02, t-test: t=2.319, df = 186) (Fig. 4C), and
or a burst stimulus (4 pulses, 100 Hz) (Snca−/− KO: 2.56 ± 0.11 μM,
n=94 sites; A30P: 2.27 ± 0.10 μM, n= 95 sites; 9 animals per geno-
type, p= 0.04, t-test: t= 2.024, df = 187) (data not shown). In the
NAc, no signiﬁcant differences in evoked [DA]o were detected be-
tween the A30P and Snca−/− KO genotypes (Fig. 4D; Snca−/−
KO: 1.51 ±0.17 μM, n= 30 sites; A30P: 1.53 ± 0.17 μM, n= 30
sites; 5 animals per genotype, p=0.92, t-test: t= 0.1021, df = 58).
The decreased release in the A30P animals compared to Snca−/− KO
in the CPu is evident in the shift to the left of the cumulative histogram
of peak [DA]o of evoked DA transients for individual sampling sites
(Fig. 4E). In CPu, the decrease in evoked [DA]o in A30P mice was not
due to variation in striatal DA uptake or DA content: no signiﬁcant dif-
ferences were seen in the decay phases of DA transients from A30P
compared to KO mice (Fig. 4F) or in DA content (Fig. 4G).To further investigate the deﬁcits in evoked [DA]o in A30P mice the
frequency sensitivity of DA release in A30P versusKOmicewas assessed
in the CPu using 5-pulse trains at frequencies ranging from 1 to 100 Hz.
These stimulation frequencies span the full physiological range, and
beyond, of DA neuron ﬁring frequencies including tonic and burst-like
activities. Although [DA]o varied with frequency according to a slight
invertedU-relationship in the CPu in both genotypes, as previously pub-
lished in wild-type C57Bl/6 mice (Exley et al., 2008), the A30P animals
showed a subtle but signiﬁcant enhancement of frequency sensitivity
(Fig. 4H). These data are consistentwith a deﬁcit in DA release probabil-
ity underlying diminished release by a single pulse and a corresponding
reduction in short-term depression that would enable greater release
during pulse trains (Rice and Cragg, 2004).
To investigate if the release deﬁcit observed in the A30Pmice is seen
at sites of release of othermonoamineswe next explored the regulation
of NE release in the vBNST. The vBNST is a site of relatively dense
Fig. 2. Immunohistochemical analysis of α-synuclein expression in the SNpc in SNCA-BAC transgenic mice. Immunoﬂuorescence shows human α-synuclein protein expression in
3 month-old A30P and hα-synmice that accurately recapitulates the pattern of endogenousα-synuclein expression in TH-positive neurons in the SNpc, seen as yellow cells in themerged
frame and clearly visible in the high-magniﬁcation insets. Age-matched Snca−/− KO animals display no α-synuclein expression.
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predominates (Kilts and Anderson, 1986). Given the potential over-
lap in catecholamine distribution and the similarity in DA and NE
voltammograms detected with FCV, it was important to characterize
the electrochemical signals detected with pharmacology. Evoked
cyclic voltammograms in each genotype had current peak potentials
characteristic of those of 2 μMNE (or DA) in calibration (Fig. 5A). We
ﬁrst optimized the stimulation protocol for subsequent studies using
C57Bl/6 wild-type animals and an inter-stimulation interval of 7 min
(Miles et al., 2002). During a stimulus train of 30 pulses at 50 Hz, the
concentration of catecholamine varied with current up to an asymp-
totic value reached at approximately 0.65 mA (Fig. 5B) The concen-
tration of evoked catecholamine also increased with frequency
during 30-pulse trains up to a maximum at 50 Hz (Fig. 5C) and at a
stimulation frequency of 50 Hz, varied with pulse number (Fig. 5D). A
stimulus protocol of 30 pulses at 50 Hz (and 0.65 mA) was selected for
subsequent studies to deliver good signal-to-noise, and with minimal
loss of release over time (data not shown).
To identify the catecholamine detected as NE rather than DA, we
explored whether the catecholamine signal in vBNST was modiﬁed by
an NE transporter uptake inhibitor, desipramine, and by anα2 adren-
ergic receptor antagonist, idazoxan. In the vBNST, either desipramine(300 nM) or idazoxan (1 μM) signiﬁcantly increased [NE]o evoked by a
30-pulse train at 50 Hz (idazoxan: n= 15–20 sites, 3 animals; p=
0.0047, t-test: t=3.051, df = 30, Fig. 5E; desipramine: n=8–10 sites,
3 animals; p=0.0247, t-test: t=2.496, df = 15, Fig. 5F). Conversely,
in CPu where evoked signals are attributab. to DA (e.g. Cragg et al.,
1997), idazoxan (1 μM) had no effect on [DA]o evoked by an identical
stimulus train (n=11–13 sites, 3 animals; Fig. 5G). It has also previous-
ly been shown that 300 nM desipramine does not affect [DA]o evoked
with these protocols in the CPu (Cragg et al., 1997). Together these
data suggest that the evoked catecholamine signals in vBNST are
attributab. to NE rather than DA.
We then compared NE transmission in vBNST of A30P versus
Snca−/− KO mice. In the vBNST of A30P slices, [NE]o evoked by a 30-
pulse train at 50 Hz were not signiﬁcantly less than those detected in
Snca−/− KO mice (KO: 0.27 ± 0.01 μM, n=79 sites; A30P: 0.25 ±
0.01 μM, n= 82 sites; 8 animals per genotype, p= 0.20, t-test: t=
1.278, df = 159) (Fig. 5H). The frequency sensitivity of NE release in
A30P and KO mice during 30-pulse trains varied with frequency but
not genotype (n=42, main effect of genotype F(1,405) = 0.03, p=0.87,
2-way ANOVA; Fig. 5I). No difference was observed between genotypes
in the NE content in the vBNST dissected from slices (A30P: 18.5 ± 4.8
pmol/ng, KO: 17.8 ± 6.9 pmol/ng, n=5 animals per genotype, p=
Fig. 3. Expression ofwild-type or A30Pα-synuclein restores susceptibility of DA neurons in Snca−/−mice toMPTP in 6-month oldmice. A, TH immunoreactivity in striatum and SNpc in
hα-syn, A30P, and Snca−/−KOmice 7 days following saline or acute dosing ofMPTP free base. TheA30P animals are similarly susceptible toMPTP lesion as hα-synmice, as evidenced by
a reduction of TH staining in the striatum and SNpc. Representative sections are shown. B, Quantitative unbiased stereological cell counts show a 30% reduction in TH + neurons in the
SNpc of hα-syn and A30P animals. The Snca−/− KO animals were resistant to MPTP treatment. Results represent mean ± SEM for 3 animals per genotype and treatment *p b 0.05. C, D
The level of striatal TH was diminished in hα-syn and A30P animals after exposure to MPTP as measured by western blot analysis of TH levels in striatal tissue, while TH expression
remained unchanged in Snca−/− KO animals. TH band intensity was controlled for β-actin expression and normalized, within-genotype, to saline-treated controls (n= 3, *p b 0.05).
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α-synuclein transgene in the LC of the A30P animals, which was absent
in the Snca−/− KO mice (Fig. 5K).
Aged A30P mice do not display catecholaminergic neuron loss nor
α-synuclein neuropathology
No changes in striatal TH or dopamine transporter (DAT) expression
were observed in the A30P mice at 6 or 18 months of age compared to
age-matched hα-syn and Snca−/− KO animals, as measured by immu-
nohistochemical analysis and western blot (Fig. 6). To investigate for
loss of catecholaminergic neurons with age, unbiased stereological cell
counts were performed on TH/hematoxylin stained cells from the
SNpc and LC of A30P, hα-syn, and Snca−/− KO mice. At 18 months of
age, no change in the number of nigral TH-positive (hα-syn: 6340 ±
709; A30P: 6668 ± 786; KO: 6467 ± 464; p= 0.89) (Fig. 7A) or
hematoxylin-stained (hα-syn: 12,147 ± 647; A30P: 14,248 ± 1067;
KO: 12,290 ± 1471; p= 0.67) cells (Fig. 7B) was observed. Similarly,
there were no changes in the number of TH-positive (hα-syn: 2257 ±
249; A30P: 2463 ± 175; KO: 2526 ± 128; p=0.95) (Fig. 7C) or
hematoxylin stained (hα-syn: 8276 ± 1284; A30P: 7884 ± 583; KO:
7908 ± 1317; p=0.96) (Fig. 7D) cells in the LC. Finally, a count of TH-
positive neurons in sub-regions of the SNpc (dorsal vs lateral vs medial
and also caudal vs rostral), based on Fu et al. (2012) to investigate any
region-speciﬁc loss which may be masked when considering the SNpc
as a whole, conﬁrmed no differences in TH-positive neurons between
genotypes at 18 months (data not shown).
We performed immunohistochemistry of A30P mice and their
Snca−/− littermate controls in parafﬁn-embedded sections to look forabnormal accumulation or aggregation of α-synuclein. In A30P mice at
18–23 months of age the antibody LB509 revealed a diffuse cytosolic
α-synuclein immunostaining in neuronal cells of the anterior olfactory
nucleus and granular cell layer of the olfactory bulb (Figs. 8A, B) and in
some pyramidal neurons in the CA2-3 region of the hippocampus (data
not shown). However, no immunostaining was detected by Syn-1 or
by pSyn#64, which detects phosphorylated α-synuclein (Figs. 8C–F).
No α-synuclein accumulation was seen in the TH-positive neurons of
themidbrain or in the spinal cord (data not shown). Immunohistochem-
ical staining for a common constituent in several types of disease-
associated inclusions, p62 ubiquitin binding protein/sequestosome 1,
revealed no pathological protein-aggregations (data not shown). GFAP
immunohistochemical staining did not show any astrogliosis and Iba-1
staining showed no increased microglial activation in the A30P mice
compared to Snca−/− KO and hα-syn mice (data not shown).
A30P mice exhibit a mild behavioral phenotype
We tested the A30P mice at several timepoints between 3 and
18 months of age for a range of motor and non-motor phenotypes asso-
ciated with PD. Before testing the animals for PD phenotypes, the mice
were ﬁrst assessed for general sensory deﬁcits which might interfere
with behavioral testing. A30P mice showed no deﬁcits in response to
tactile stimulation, mild irritation/burning sensations stimulated by
ammonia, or quinine-induced taste aversion as compared to hα-syn
and Snca−/− KO controls (data not shown). Aging A30P mice up to
18 months of age were tested for the presence of motor phenotypes.
Animals were tested using novelty-induced locomotor activity, forepaw
stride length, and rotarod. The A30P mice did not demonstrate any
Fig. 4. Electrically evoked dopamine transients and regulation of [DA]o by ﬁring frequency in 3-month old hα-syn, SNCAA30P and Snca−/−KOmeasured by FCV. A,Meanproﬁles of [DA]o
versus time (mean ± SEM) after a single pulse (0.2 μs; arrow) in the dorsal striatum (CPu). In CPu, there is no difference in peak [DA]o transiently evoked by single pulses in hα-synmice
compared to age-matched KO littermates (p= 0.2265, n= 60 (5 animals per genotype)). B, No signiﬁcant differences seen in mean peak [DA]o evoked by a single pulse (1p) in hα-syn
transgenic mice compared to KO littermates in the NAc. (p= .8680, n= 18 (5 animals per genotype)). C, Mean proﬁles of [DA]o versus time (mean ± SEM) after a single pulse (0.2 μs;
arrow) in the dorsal striatum (CPu). In CPu, peak [DA]o transiently evoked by single pulses is slightly less in A30P than age-matched KO littermates (*p b 0.05, KO, n= 96; A30P, n=
92 (9 animals per genotype)). D, No signiﬁcant differences seen in mean peak [DA]o evoked by a single pulse (1p) in A30P transgenic mice compared to KO littermates in the NAc. E,
Cumulative histogram of peak [DA]o of evoked DA transients in the CPu in KO vs A30P mice for individual sampling sites. F, Comparison of the rates of decay of concentration-matched
DA transients suggests that DA uptake rates are not signiﬁcantly different between the two genotypes (n= 5, p N 0.05). G, No differences were observed in DA content (pmol per μg of
protein) in the CPu or NAc dissected from striatal slices. Data shown represent mean ± SEM from Snca KO and SNCA A30P mouse samples (n=8–10, p N 0.05). H, Regulation of [DA]o
byﬁring frequency in theCPu.Meanpeak [DA]o during5 pulse trains (1–100 Hz) in theCPu variedwith frequency in both genotypes in control conditions,with a slightly greater frequency
sensitivity observed in A30P transgenic mice at 25 Hz. Data were normalized within genotype to the 1p value (n=3, *p b 0.05).
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hα-syn and Snca−/− KOmice (n= 5–10, interaction effects of age and
genotype: F(4,76) = 0.72, p= 0.58) (Fig. 9A).When assessed by forepaw
stride length, no differences were detected between genotypes at any
age (n= 5–10, interaction effect of age and genotype: F(4,78) = 0.34,
p=0.85) (Fig. 9B). Likewise, when tested on an accelerating rotarod
paradigm, 18 month A30P animals displayed no differences in motor
learning or performance when compared to age-matched hα-syn and
Snca−/− KO animals, as analyzed by repeated measures two-way
ANOVA with Bonferroni post hoc test (n= 4–10, main effect of
genotype: F(2,17) = 0.29, p= 0.75) (Fig. 9C).Finally, the A30P animals were subjected to behavioral assays to test
for non-motor symptoms associated with PD. Non-motor PD symptoms
we wished to model include neuropsychiatric disorders such as anxiety
and depression, gastrointestinal dysfunction, cognitive impairments,
and sleep disturbances. The A30P and KO mice were shown to exhibit
an anxiety-like phenotype by quantifying time spent in the open-arm
of the elevated plus maze compared to the hα-syn animals at 6 months
of age (main effect of genotype: F(2, 75) = 31.36, p b 0.001; interaction
effects of age and genotype: F(4,75) = 2.25, p=0.0715; 2-way
ANOVA with Bonferroni post hoc analysis). However, all genotypes
showed an increase in anxiety with age (n=10–13, main effect of age:
Fig. 5. Electrically evoked noradrenergic transients and regulation of norepinephrine (NE) signals by ﬁring frequency in 3-month old SNCA-A30P and Snca−/− KOmicemeasured by FCV.
A, Cyclic voltammograms from a calibration using 2 μMNE (black), and 30pulses at 50 Hz in SncaKO(red) and A30P (blue) slices. B,MaximalNE release as a function of current amplitude.
Each data point was obtained with a 30-pulse, 50 Hz stimulation (n= 6 C57Bl/6 animals). C, Maximal release as a function of stimulation frequency. Each data point was obtained with a
30-pulse stimulation, and a current amplitude of 0.65 mA (n= 5 C57Bl/6 animals). D, Maximal release as a function of pulse number. Each data point was obtained with a stimulation
frequency of 50 Hz, and current amplitude of 0.65 mA (n= 6 C57/Bl6 animals). E, Mean [NE]o versus time evoked by 30 pulses at 50 Hz in vBNST of C57/Bl6 mice in control conditions,
in the presence of theα2 adrenergic antagonist, idazoxan (1 μM). Idazoxan signiﬁcantly increased peak [NE]o in the vBNST (n= 3animals, **p b 0.01). F,Mean [NE]o versus time evoked by
30 pulses at 50 Hz in vBNST of C57Bl/6mice in control conditions and in the presence of 300 nMdesipramine. Desipramine signiﬁcantly increased peak [NE]o in the vBNST (n= 3animals,
*p b 0.05). G,Mean [DA]o versus time evoked by30pulses at 50 Hz in theCPu of C57/Bl6mice in control conditions and in thepresence ofα2 adrenergic antagonist, idazoxan (1 μM). Unlike
in the vBNST, idazoxanproduces no change inpeak [DA]o in theCPu (n= 3animals). H,Mean proﬁles of [NE]o versus time (mean ± SEM)after a 30 pulse, 50 Hz stimulation (arrow) in the
ventral bed nucleus of the stria terminalis (BNST). In vBNST, a very slight 8% difference was observed in peak [NE]o transiently evoked by 30 pulses at 50 Hz in A30P compared to age-
matched KO littermateswhichwas not signiﬁcant (p N 0.05; KO, n= 79 sites; A30P, n= 82 sites (8 animals per genotype)). I,Mean peak [NE]o ± SEM vs. frequency during 30 pulse trains
(10–100 Hz) in the vBNST varied with frequency in both genotypes in control conditions. No differences in frequency sensitivity were seen in A30P transgenic mice compared to KO an-
imals (p N 0.05; 8 animals per genotype). J, Cumulative histogram of peak [NE]o of evoked NE transients in the vBNST in KO vs A30P mice for individual sampling sites. K, Immunohisto-
chemical analysis in coronal mouse sections conﬁrmed α-synuclein transgene expression in the LC in SNCA-A30Pmice; α-synuclein expression was not seen in Snca−/− KO animals.
202 T.N. Taylor et al. / Neurobiology of Disease 62 (2014) 193–207F(2,75) = 2.66, p=0.0763, 2-way ANOVAwith Bonferroni post hoc analy-
sis) (Fig. 9D). Animals were tested for altered behavior in the tail suspen-
sion test. At both 6 months and 10–13 months of age, there was no
difference found between the immobility times of hα-syn, A30P, and
Snca−/− KO in the tail suspension test (n=10–13, interaction effects
of age and genotype: F(2,51) = 1.62, p=0.208, 2-way ANOVA with
Bonferroni post hoc analysis) (Fig. 9E).
When tested for differences in circadian rhythms, no signiﬁcant
differences were observed in the A30P animals compared to Snca−/−
KO or hα-syn in activity during the light phase, acute response to
light, re-entrainment to new light–dark cycles, or activity during con-
stant light using methods and analyses as previously described (Oliver
et al., 2012) (data not shown). However, the A30P animals were more
active in wheel running during the normal 12 h–12 h normal light–
dark cycle, showing a trend for increased activity throughout the darkphase, reaching statistical signiﬁcance, as analyzed by repeated mea-
sures two-way ANOVA with Bonferroni post hoc test, during hours 4
and 5 of darkness (hours 15 and 16, n=5, main effect of genotype:
F(2,12) = 3.52, p= 0.0627, interaction effect of time and genotype:
F(46,276) = 1.73, p= 0.004; Fig. 9F). Interestingly, this effect related spe-
ciﬁcally towheel running and not activity in the dark per se as it was not
seen during dark phase activity when mice were housed in locomotor
cages and activity measured over 24 h periods of normal 12-h light/
dark cycle (12:12 LD), as analyzed by repeated measures two-way
ANOVA with Bonferroni post hoc test (Fig. 9G; n= 8, main effect of
genotype: F(2,21) = 0.64, p=0.5353).
To study prevalence of a speciﬁc GI disturbance, constipation, in the
A30P mice, all three genotypes of mice were behaviorally examined for
stool frequency at 4, 10–13, and 15–18 months of age. Additionally,
stool was analyzed for water content and dry weight at these
Fig. 6. Immunohistochemical and western blot analysis of striata in aged (18-month old) hα-syn, A30P, and Snca−/− KOmice. A, TH immunoreactivity was unchanged at 18 months of
age. Western blot analysis of striatal lysates from hα-syn, A30P, and Snca−/− KOmice show also no differences in TH expression with age. B, DAT immunoreactivity was unchanged at
18 months of age. Similarly, western blot analysis of striatal lysates fromhα-syn, A30P, and Snca−/− KOmice does not demonstrate a reduction in DAT expressionwith age. Analysiswas
performed on 3 animals per genotype at each age. Representative sections are shown. Columns represent percentage change from the 6-month old hα-syn control. Results represent the
mean ± SEM for three animals per genotype at each age. For western blot analysis, 10 μg protein was loaded per lane.
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genotypes have decreased stool frequency with age (n= 5–8, interac-
tion effects of age and genotype: F(4, 65) = 0.88, p= 0.479, 2-way
ANOVAwith Bonferroni post hoc analysis) (Fig. 9H). Similarly, no differ-
ences were found between genotypes in the dry weight of stool or stool
water content at any age (n= 5–8, interaction effects of age and geno-
type for dry weight: F(4,64) = 0.54, p=0.70; interaction effects of
age and genotype for water content: F(4,62) = 0.44, p=0.78, 2-wayFig. 7. Stereological counts of SNpc and LC in aged hα-syn, A30P, and Snca−/− KOmice. A, B N
18 months of age inA30P animals comparedwith hα-syn andKOanimals. C, D, Similarly, no diff
LC at 18 months of age between the three genotypes. Results represent the mean± SEM for 5ANOVA with Bonferroni post hoc analysis, data not shown). The
presence of cognitive deﬁcits in the A30P animals was tested for by
measuring spontaneous alternation in the T-maze. At 3 months, 10–
13 months, and 15–18 months of age, the A30P mice display no deﬁcits
in spontaneous alternation when compared to age matched hα-syn and
Snca−/− KO mice (n=10–13, interaction effects of age and genotype:
F(4,77) = 0.25, p=0.91, 2-way ANOVAwith Bonferroni post hoc analysis)
(Fig. 9I).o differences were seen in TH-positive cells (A) or hematoxylin-positive (B) in the SNpc at
erenceswereobserved TH cell number (C) or hematoxylin-positive cell numbers (D) in the
animals per genotype at each age, p N 0.05.
Fig. 8. Absence of synuclein pathology in 23-month old A30P transgenic animals. A diffuse cytosolic α-synuclein immunostaining was seen in neuronal cells of the anterior olfactory nu-
cleus and granular cell layer of the olfactory bulbwith antibody LB509 (A), but not by Syn-1 (C), or pSyn#64 against the phosphorylatedα-syn (E). Magniﬁcation in A-F ×40, inserts show
higher-power magniﬁed image ×200.
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Here, we have exploited bacterial artiﬁcial chromosome (BAC) tech-
nology to create transgenic mouse lines to investigate the region-
speciﬁc role of α-synuclein and the effect of the A30Pmutation on dopa-
mine neurotransmission. We show that expression of the A30P mutant
form ofα-synucleinwith a correct spatial pattern results in dysregulation
of dopamine neurotransmission in the dorsal, but not ventral, striatum.
We propose this model recapitulates the very earliest pre-symptomatic
region-speciﬁc dysfunction of the nigrostriatal dopamine system in PD.
Transgene expression in BACmice is controlled by endogenous gene
regulatory elements in genomic DNA, resulting in physiological protein
expression. The inclusion of 18 kb of 5′ promoter ensures the presence
of the NACP-Rep1 repeat element which lies approximately 10 kb
upstreamof the transcriptional start site, and is an important regulatory
element (Jakes et al., 1994; Ueda et al., 1993). The hα-syn line and A30P
transgenic lines express the protein at a similar level, allowing a direct
comparison between their function on a Snca−/− background. The
use of the Snca−/− background avoids the previously-reported con-
founding effect of endogenous mouseα-synuclein expression on trans-
gene function (Cabin et al., 2005). Both transgenes have a regional
pattern of α-synuclein expression which is very close to that of endog-
enousmouseα-synuclein in wild-typemice, with expression in regions
that include the SNpc, albeit at a lower level than endogenous α-synuclein. In a recent study, transgenic mice expressing human
wildtype α-synuclein, or the A30P mutated form, were created
using a PAC containing the entire human SNCA gene, which resulted
in modest levels of transgenic protein (1.3 to 2-fold compared to en-
dogenous mouse Snca) (Kuo et al., 2010). Taken together, these re-
sults conﬁrm that the BAC transgenic approach avoids the
considerable overexpression of α-synuclein transgene seen when
using cDNA-based transgenic models.
Previous studies have developed transgenic mouse models over-
expressing human A30P α-synuclein that exhibit a range of pathologies
and behaviors (Gomez-Isla et al., 2003; Lee et al., 2002; Matsuoka et al.,
2001; Neumann et al., 2002; Yavich et al., 2005). Such studies have dem-
onstrated that A30P α-synuclein expressed under the PrP or Thy-1 pro-
moters exhibit varied motor abnormalities (Gomez-Isla et al., 2003;
Neumann et al., 2002; Rathke-Hartlieb et al., 2001; Yavich et al., 2005).
When tested for non-motor deﬁcits, results have differed based on pro-
moter; animals expressing A30P α-synuclein from the Thy-1 promoter
display cognitive deﬁcits on the Morris water maze, while animals
made using the PrP promoter do not (Freichel et al., 2007; Gomez-Isla
et al., 2003). A homozygous double-transgenic PAC-A30P model shows
decreased stool frequency and colonic motility time, but not hyposmia
or autonomic dysfunction (Kuo et al., 2010).
The range of pathologies and behaviors observed in previous A30P
models may be due to overt synuclein toxicity resulting from high
Fig. 9. A30Pmice display a verymild behavioral phenotype. A, A30P mice have similar total locomotor activity at all ages when introduced into a novel environment as compared to age-
matched hα-syn and Snca−/−KO controls. Results represent themean number of ambulations ± SEM for 10–13mice per genotype. B, No deﬁcits in forepaw stride lengthwere apparent
at 3 months or 10–13 months of age in A30Pmice, compared to age-matched hα-syn and Snca−/− KO controls. Results represent average stride length (cm) ± SEM for 8–10 animals per
genotype. C, No differenceswere seen inmotor learning or performance on the rotarod at 18months of age. Results represent latency to fall (sec) ± SEM for 4–10 animals per genotype. D,
At 6 months of age, the hα-synmice spent a greater percentage of their time in the open arms of the elevated plusmaze as compared to age-matched A30P and Snca KO animals over the
5 min test period. All genotypes display an increased anxiety-like phenotype with age. Results represent the mean percentage of time spent in the open arms ± SEM for 10–13mice per
genotype. **p b 0.01 E, All genotypes had similar immobility times in the tail suspension test, which remains unchanged with age. Results represent mean time (s) ± SEM for 10–13mice
per genotype. F, A30P mice display increased wheel running during hours 16–17 of their light–dark cycle compared to hα-syn and Snca−/− KO mice at 12 months of age. Results rep-
resent total activity counts ± SEM for 5 animals per genotype *p b 0.05, **p b 0.01. G, A30Pmice display normal circadian activity levels compared to hα-syn and KO animals at 12 months
of age. Results represent total ambulations ± SEM for 8 animals per genotype. H, A30Pmice do not display differences in stool frequency compared to age-matched hα-syn and Snca−/−
KO controls. Results represent average stool frequency ± SEM for 5–11 animals per genotype. I, A30Pmice donot display deﬁcits in spontaneous alternation asmeasured by the T-maze at
3, 10–13, or 15–18 months of age when compared to age-matched hα-syn or Snca KOmice. Results represent the mean alternation ± SEM for 10–13 animals per genotype at each age.
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minergic system or on behavioral phenotypes relevant to PD. In the
present study the alterations in dopamine neurotransmission in SNCA-
A30P mice were accompanied by a mild increase in wheel-running
activity during the dark phase, a phenotype previously associated with
deﬁcits in the dopaminergic system (Knab et al., 2009, 2012). No signif-
icant differences were seen in anxiety, circadian rhythm, depressive-
like behavior, gastrointestinal function, cognition, or motor phenotypes
when tested against age-matched Snca−/− KO and hα-syn controls.α-Synuclein speciﬁcally regulates dopamine release in dorsal striatum
Our laboratory has previously shown that while Snca−/− KO ani-
mals do not display differences in electrically evoked [DA]o in the CPu
as compared to wildtype C57Bl/6 mice, mice that are either α/γ-
synuclein double-null or α/β/γ-synuclein triple-null do have enhanced
levels of electrically evoked DA release (Anwar et al., 2011; Senior et al.,
2008). Conversely, A30Pmice here displayed a 13% reduction in evoked
[DA]o in the CPu when compared to age-matched Snca KO mice. Since
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ent, and the A30P andwild-typeα-synuclein are expressed at compara-
ble levels, the changes in DA transmission in A30P mice are speciﬁc to
the presence of the A30P point mutation and not the human transgene.
Mice lacking α-synuclein have been shown to exhibit a mild reduction
in striatal tissue levels of DA (Abeliovich et al., 2000; Cabin et al.,
2002) although this was not conﬁrmed by a third study (Specht and
Schoepfer, 2001). The change in evoked [DA]o was not seen in the
NAc, and hence appears to be speciﬁc to nigrostriatal DA tracts which
are preferentially vulnerable in PD. The enhanced frequency sensitivity
of DA release seen in the CPu of the A30Pmice together with the reduc-
tion in release by a single pulse but the lack of change in DA content,
suggests that DA release probability is reduced in this genotype. A sim-
ilar modiﬁcation to frequency sensitivity of [DA]o has recently been
identiﬁed in CPu for mice that overexpress a different human SNCAmu-
tation, A53T (in a PrP promotermodel) (Platt et al., 2012). These effects
may represent an important change seen in synuclein-mediated PD
pathophysiology. These changes in DA transmission contrast, however,
with those reported for exocytosis of glutamate (Nemani et al., 2010)
for which the A30P mutation decreases the ability of α-synuclein to in-
hibit exocytosis from cultured hippocampal neurons. This contradiction
emphasizes the critical importance of undertaking studies in the neuro-
transmitter system of most relevance to a disease.
Given that PD pathology is not restricted to the dopaminergic sys-
tem, we also examined evoked [NE]o in the ventral bed nucleus stria
terminalis (vBNST). Synuclein accumulation and Lewy body formation
occur early in structures highly prone to neurodegeneration, including
the LC; LC degeneration occurs and can be more severe than nigral de-
generation (Braak et al., 2002, 2003; Fernagut and Chesselet, 2004;
Rye and DeLong, 2003). Previous FCV work has demonstrated that NE
can act as a volume transmitter in the vBNST, but NE release has not
been clearly distinguished from DA (Kilts and Anderson, 1986; Miles
et al., 2002). The effects of the α2 adrenergic antagonist, idazoxan, and
the NET inhibitor, desipramine, on voltammetric signals in vBNST
strongly suggest that voltammetric catecholamine signals were
attributab. to NE rather than DA. We found that evoked [NE]o or their
frequency sensitivity were not different in A30P animals compared to
age-matched Snca−/− KO controls conﬁrming the region-speciﬁc role
of α-synuclein on neurotransmission.
The A30P α-synuclein mutation in PD
The α-synuclein A30P point mutation causes very rare forms of au-
tosomal dominant PD (Kruger et al., 1998, 2001). Compared to the
A53T-affected patients, A30P patients are thought to exhibit a milder
phenotype and later age of onset (Kruger et al., 2001), although the
ﬁrst post-mortem examination of an A30P PD patient brain recently
showed strong neuropathological similarities to sporadic PD, with the
A30P pathology being more severe (Seidel et al., 2010). The A30P α-
synucleinmutation has been shown to preventα-synuclein binding ve-
sicular membranes and to promote oligomerization rather than
ﬁbrillization (Conway et al., 2000; Jensen et al., 1998). When we chal-
lenged the hα-syn and A30P mice with an acute dose of MPTP both
the wild-type and A30P α-synuclein transgenes restored susceptibility
to the otherwise resistant Snca−/− line, supporting the concept that
the lipid binding ability of α-synuclein does not mediate MPTP toxicity
and that A30P α-synuclein is active and able to fully complement the
Snca−/− KO background (Dauer et al., 2002; Nemani et al., 2010). Pre-
viously, wildtype human α-synuclein and A53T mutated human α-
synuclein have been shown to restore MPTP susceptibility in
Snca−/− KO mice (Thomas et al., 2011). Here, we have demonstrated
that human A30P synuclein is also able to restore neuronal vulnerability
to MPTP in vivo.
The A30Pmutation has been shown to relieve the inhibitory effect of
α-synuclein on synaptic vesicle exocytosis in glutamatergic hippocam-
pal neurons in vitro (Nemani et al., 2010), and it has been suggested thatthe inability of A30P-mutated α-synuclein to bind lipid membranes
may abolish synaptic localization rendering it inactive (Fortin et al.,
2004; Nemani et al., 2010). This phenomenon in non-dopaminergic
neurons may be due to a number of factors including elimination of
α-synuclein synaptic localization, failure to undergo structural transi-
tion, or loss of membrane interaction (Fortin et al., 2004; Jo et al.,
2002; Outeiro and Lindquist, 2003).We observe that the A30Pmutation
affects DA neurotransmission in the nigrostriatal DA neurons projecting
from the SNpc to the dorsal striatum (CPu), but not in mesolimbic DA
neurons projecting from the VTA to the ventral striatum and NAc, sug-
gesting that A30P α-synuclein may act through a gain of function in
the dopaminergic nigrostriatal tract in a highly region-speciﬁc manner.
Its outcome is opposite to that of deletion of α/β/γ-synuclein, and with
matching region speciﬁcity (Anwar et al., 2011).
Conclusions
Our SNCA-A30P BAC mouse model reﬂects region-speciﬁc chang-
es seen in the dopaminergic system as a result of dysfunctional α-
synuclein. Previous α-synuclein transgenic mouse models employed
strong heterologous promoters, resulting in high levels of α-synuclein
targeted to speciﬁc areas of the brain. Overexpression of α-synuclein
(ranging up to 30-fold) constitutes a usefulmodel ofα-synuclein toxicity,
but has limited physiological relevance for studying the effects of α-
synuclein in PD. Additionally, regions with the most severe pathology
in previousα-synuclein transgenic mice, such as motor neurons and spi-
nal cord (Giasson et al., 2002; vander Putten et al., 2000), do not correlate
with the typical regions of preferential pathology observed in PD. Taken
together, these complications in previous A30P models have potentially
occluded the mechanisms that represent those occurring in PD where
expression levels and patterns aremoremoderate. BAC-based transgenic
models allow for cell-speciﬁc and developmentally-appropriate expres-
sion closely recapitulating the native spatial distribution of expression.
The subtle changes in dopaminergic neurotransmission observed in the
A30P BAC model, despite the absence of α-synuclein-immunoreactive
Lewy body-like inclusions, suggest aberrations in dopamine physiology
make an important contribution to PD in the absence of protein aggrega-
tion pathology.
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